Baricitinib for dermatitis

17th May 2021 by Dr Louise Hudman

Baricitinib for dermatitis

NICE has released a new guideline on the use of Baricitinib in moderate to severe atopic dermatitis. Baricitinib is a Janus kinase (JAK) inhibitor.

As JAK is essential for certain cytokine signalling, by disrupting JAK, you disrupt cytokine signalling and thus disrupt the body’s immune response.

It will be used fourth line (after normal GP treatments, phototherapy and 1 other systemic immunosuppressant).

Read more

No credit card details needed – it takes two minutes.

Join free trial


Already a member? Login to view this content.


Related content

"Before I used LocumDeck, some practices used to ignore my terms and conditions and add bookings to their diaries that they hadn't confirmed with me. Now, my terms and conditions get sent out with every communication and I can confirm sessions by email really easily. I love having a paper trail that's easy to follow – no more endless hunts through random emails. "

Dr Paula N, GP

See the full list of features within our NASGP membership plans